Global Respiratory Drug Market Research and Forecast 2018-2023
The global respiratory drug market is expected to grow significantly during forecast period. Several respiratory drugs are given by inhalation, although enteral, parenteral, transdermal, or topical routes of administration may be used for some respiratory drugs. Inhalation route of administration has various advantages over systemic administration such as a smaller dose can be used, adverse effects are often reduced, the drug is delivered quickly to lung tissue or the bloodstream, administration is painless, and delivery is usually safe and convenient. The respiratory drugs are used to treat several respiratory diseases such as asthma, COPD (chronic obstructive pulmonary disease), cystic fibrosis, chronic bronchitis, emphysema and allergic rhinitis.
Major factors contributing to the growth of the global respiratory drug market include increasing prevalence of chronic respiratory diseases such as asthma and COPD. This is mainly owing to increasing smoking and pollution across the globe. Growing cases of respiratory diseases in new born and children and changing lifestyle and rise in obesity are fueling the market growth. Moreover, innovations and development of new drugs such as Dupilumab for severe asthma is significantly contributing in the market growth. However, reimbursements and strict government regulations and limited awareness and availability are some of the factors hindering the growth of the market. Lack of awareness among population of emerging countries is hampering the growth of the global respiratory drug market. However, robust pipeline products and emerging markets is expected to fuel the market growth in the near future.
The global respiratory drug market can be segmented on the basis of drug, drug class, route of administration, and end user. The market by drug class is segmented on the basis of currently available medication options for the treatment of symptoms of respiratory disorders reduce the symptoms for disease control. Generally, six classes of drug and nasal saline are used to treat asthma, oral and topical H1-antihistamines, mast cell stabilizers (i.e., cromones), decongestants, anticholinergic agents, and leukotriene inhibitors. Medications used for asthma are characteristically administered orally or intranasally. The intranasal route allows higher concentrations of the drug to be delivered, thus minimizing systemic side effects.
The global respiratory drug market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America holds a dominant position in the global respiratory drug market, followed by Europe. This is mainly owing to rising prevalence of chronic respiratory diseases in the region, especially in the US. The increasing research and development in respiratory drug development is expected to further drive the growth of the respiratory drug market in the region. Asia Pacific is projected to exhibit the fastest growth in the global market over the forecast period. Some of the major factors that are significantly contributing in the growth of the market in Asia Pacific are increasing investment by pharmaceuticals companies. For instance, in India, India’s Cipla expects to double respiratory drug sales by 2020. Further, Indian companies such as Dr Reddy’s Laboratories, Lupin and Cipla are expected to build expertise in the respiratory drug market.
Some of the key players operating in the global respiratory drug market are GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, AstraZeneca PLC, Merck & Co., Inc., Novartis International AG, Omron Corporation, and Sunovion Pharmaceuticals Inc. In order to sustain in the competitive market, these players adopt various strategies such as acquisitions, mergers, expansions, joint ventures, and product development, among others. For instance,
RESEARCH METHODOLOGY
The market study of respiratory drug market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic public databases such as American Academy of Family Physicians (aafp.org), org, and effectivenessevaluation.org.
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
Supplier Websites such as Alibaba, amazon for pricing analysis
The report is intended for hospitals, private companies, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.
MARKET SEGMENTATION:
Global respiratory drug market is segmented on the basis of regional outlook and following segments:
Global Respiratory drug market Research and Analysis, By Drug
Global Respiratory drug market Research and Analysis, By Drug Class
Global Respiratory drug market Research and Analysis, By Route of Administration
Global Respiratory drug market Research and Analysis, By End User
Global Respiratory drug market Research and Analysis, By Region
THE REPORT COVERS:
Comprehensive research methodology of global respiratory drug market
This report also includes detailed and extensive market overview with key analyst insights
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations
Analysis of regional regulations and other government policies impacting the global respiratory drug market
Insights about market determinants which are stimulating the global respiratory drug market
Detailed and extensive market segments with regional distribution of forecasted revenues
Extensive profiles and recent developments of market players
Major factors contributing to the growth of the global respiratory drug market include increasing prevalence of chronic respiratory diseases such as asthma and COPD. This is mainly owing to increasing smoking and pollution across the globe. Growing cases of respiratory diseases in new born and children and changing lifestyle and rise in obesity are fueling the market growth. Moreover, innovations and development of new drugs such as Dupilumab for severe asthma is significantly contributing in the market growth. However, reimbursements and strict government regulations and limited awareness and availability are some of the factors hindering the growth of the market. Lack of awareness among population of emerging countries is hampering the growth of the global respiratory drug market. However, robust pipeline products and emerging markets is expected to fuel the market growth in the near future.
The global respiratory drug market can be segmented on the basis of drug, drug class, route of administration, and end user. The market by drug class is segmented on the basis of currently available medication options for the treatment of symptoms of respiratory disorders reduce the symptoms for disease control. Generally, six classes of drug and nasal saline are used to treat asthma, oral and topical H1-antihistamines, mast cell stabilizers (i.e., cromones), decongestants, anticholinergic agents, and leukotriene inhibitors. Medications used for asthma are characteristically administered orally or intranasally. The intranasal route allows higher concentrations of the drug to be delivered, thus minimizing systemic side effects.
The global respiratory drug market is further analyzed on the basis of the geographical regions that are contributing significantly towards the growth of the market. North America holds a dominant position in the global respiratory drug market, followed by Europe. This is mainly owing to rising prevalence of chronic respiratory diseases in the region, especially in the US. The increasing research and development in respiratory drug development is expected to further drive the growth of the respiratory drug market in the region. Asia Pacific is projected to exhibit the fastest growth in the global market over the forecast period. Some of the major factors that are significantly contributing in the growth of the market in Asia Pacific are increasing investment by pharmaceuticals companies. For instance, in India, India’s Cipla expects to double respiratory drug sales by 2020. Further, Indian companies such as Dr Reddy’s Laboratories, Lupin and Cipla are expected to build expertise in the respiratory drug market.
Some of the key players operating in the global respiratory drug market are GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, AstraZeneca PLC, Merck & Co., Inc., Novartis International AG, Omron Corporation, and Sunovion Pharmaceuticals Inc. In order to sustain in the competitive market, these players adopt various strategies such as acquisitions, mergers, expansions, joint ventures, and product development, among others. For instance,
RESEARCH METHODOLOGY
The market study of respiratory drug market is incorporated by extensive primary and secondary research conducted by research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity in our reports.
Secondary sources include:
Financial reports of companies involved in the market
Authentic public databases such as American Academy of Family Physicians (aafp.org), org, and effectivenessevaluation.org.
Whitepapers, research-papers, and news blogs
Company websites and their product catalogue
Supplier Websites such as Alibaba, amazon for pricing analysis
The report is intended for hospitals, private companies, government organizations for overall market analysis, and competitive analysis. The report provides in-depth analysis on pricing, market size, intended quality of the product preferred by consumers, initial norms and vehicle segment. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models delivering insights into the market for better business decisions.
MARKET SEGMENTATION:
Global respiratory drug market is segmented on the basis of regional outlook and following segments:
Global Respiratory drug market Research and Analysis, By Drug
Global Respiratory drug market Research and Analysis, By Drug Class
Global Respiratory drug market Research and Analysis, By Route of Administration
Global Respiratory drug market Research and Analysis, By End User
Global Respiratory drug market Research and Analysis, By Region
THE REPORT COVERS:
Comprehensive research methodology of global respiratory drug market
This report also includes detailed and extensive market overview with key analyst insights
Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations
Analysis of regional regulations and other government policies impacting the global respiratory drug market
Insights about market determinants which are stimulating the global respiratory drug market
Detailed and extensive market segments with regional distribution of forecasted revenues
Extensive profiles and recent developments of market players
1. REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. MARKET DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. PIPELINE ANALYSIS
2.4. TOP RESPIRATORY DRUGS ANALYSIS
2.5. RESPIRATORY DISEASES
2.5.1. ASTHMA
2.5.2. COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)
2.5.3. CYSTIC FIBROSIS
2.5.4. CHRONIC BRONCHITIS
2.5.5. EMPHYSEMA
2.5.6. ALLERGIC RHINITIS
2.5.7. OTHER
2.6. REGULATIONS
2.6.1. UNITED STATE
2.6.2. CHINA
2.6.3. INDIA
2.6.4. JAPAN
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. HIGH PREVALENCE OF CHRONIC RESPIRATORY DISEASES SUCH AS ASTHMA AND COPD
3.1.2. GROWING CASES OF RESPIRATORY DISEASES IN NEW BORN AND CHILDREN
3.1.3. CHANGING LIFESTYLE AND RISE IN OBESITY
3.1.4. INNOVATIONS AND DEVELOPMENT OF NEW PRODUCTS
3.2. RESTRAINTS
3.2.1. REIMBURSEMENTS AND STRICT GOVERNMENT REGULATIONS
3.2.2. LIMITED AWARENESS AND AVAILABILITY
3.3. OPPORTUNITIES
3.3.1. ROBUST PIPELINE PRODUCTS
3.3.2. EMERGING MARKETS
4. MARKET SEGMENTATION
4.1. RESPIRATORY DRUGS MARKET BY DRUG
4.1.1. ADVAIR
4.1.2. SYMBICORT TURBUHALER
4.1.3. SPIRIVA
4.1.4. XOLAIR
4.1.5. VENTOLIN
4.1.6. PULMICORT
4.1.7. ORKAMBI
4.1.8. RELVAR/BREO ELLIPTA
4.1.9. SINGULAIR
4.1.10. ESBRIET
4.1.11. KALYDECO
4.1.12. EPIPEN
4.1.13. OFEV
4.1.14. OTHER
4.2. RESPIRATORY DRUGS MARKET BY DRUG CLASS
4.2.1. ANTICHOLINERGICS
4.2.2. ANTIHISTAMINES
4.2.3. BETA2 AGONISTS
4.2.4. ANTIASTHMATIC COMBINATIONS
4.2.5. CORTICOSTEROIDS
4.2.6. LEUKOTRIENE INHIBITORS
4.2.7. MAST CELL STABILIZERS
4.2.8. PHOSPHODIESTERASE 4 (PDE4) INHIBITORS
4.2.9. BRONCHODILATORS
4.2.10. DECONGESTANTS
4.2.11. EXPECTORANTS
4.2.12. OTHER RESPIRATORY DRUGS
4.3. RESPIRATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION
4.3.1. ORAL RESPIRATORY DRUGS
4.3.2. INJECTABLE RESPIRATORY DRUGS
4.3.3. INHALABLE RESPIRATORY DRUGS
4.4. RESPIRATORY DRUGS MARKET BY END USERS
4.4.1. HOSPITALS
4.4.2. HOME CARE
4.4.3. OTHER END USERS
5. COMPETITIVE LANDSCAPE
5.1. MARKET SHARE ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. AIR LIQUIDE
7.2. ARADIGM CORPORATION
7.3. ASTRAZENECA PLC
7.4. BAXTER INTERNATIONAL INC.
7.5. BEXIMCO PHARMACEUTICALS LTD.
7.6. BOEHRINGER INGELHEIM GMBH
7.7. COMPUMEDICS LTD.
7.8. COVIDIEN PLC
7.9. DRAGER MEDICAL GMBH
7.10. F. HOFFMANN-LA ROCHE LTD
7.11. FISHER AND PAYKEL HEALTHCARE CORP. LTD
7.12. GE HEALTHCARE LIMITED
7.13. GENENTECH, INC.
7.14. GLAXOSMITHKLINE PLC
7.15. GRIFOLS, S.A.
7.16. HAMILTON MEDICAL AG
7.17. INVACARE CORPORATION
7.18. KONINKLIJKE PHILIPS N.V.
7.19. MERCK AND CO.
7.20. METHAPHARM, INC.
7.21. MYLAN N.V.
7.22. NABRIVA THERAPEUTICS PLC
7.23. NEPHRON PHARMACEUTICALS CORPORATION
7.24. NOVABIOTICS LTD.
7.25. NOVALUNG GMBH
7.26. NOVARTIS INTERNATIONAL AG
7.27. OMRON CORPORATION
7.28. OPKO HEALTH, INC.
7.29. OREXO AB
7.30. OTSUKA PHARMACEUTICALS INC.
7.31. PALOBIOFARMA S.L.
7.32. PFIZER INC.
7.33. SAVARA, INC.
7.34. SUMITOMO DAINIPPON PHARMA CO., LTD.
7.35. SUNOVION PHARMACEUTICALS INC.
7.36. TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.37. TEVA PHARMACEUTICALS INC.
7.38. UNITED THERAPEUTICS CORPORATION
7.39. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
7.40. VERONA PHARMA PLC
7.41. VERTEX PHARMACEUTICALS INC.
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
2. MARKET OVERVIEW AND INSIGHTS
2.1. MARKET DEFINITION
2.2. ANALYST INSIGHTS & CURRENT MARKET TRENDS
2.2.1. KEY FINDINGS
2.2.2. RECOMMENDATION
2.2.3. CONCLUSION
2.3. PIPELINE ANALYSIS
2.4. TOP RESPIRATORY DRUGS ANALYSIS
2.5. RESPIRATORY DISEASES
2.5.1. ASTHMA
2.5.2. COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE)
2.5.3. CYSTIC FIBROSIS
2.5.4. CHRONIC BRONCHITIS
2.5.5. EMPHYSEMA
2.5.6. ALLERGIC RHINITIS
2.5.7. OTHER
2.6. REGULATIONS
2.6.1. UNITED STATE
2.6.2. CHINA
2.6.3. INDIA
2.6.4. JAPAN
3. MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. HIGH PREVALENCE OF CHRONIC RESPIRATORY DISEASES SUCH AS ASTHMA AND COPD
3.1.2. GROWING CASES OF RESPIRATORY DISEASES IN NEW BORN AND CHILDREN
3.1.3. CHANGING LIFESTYLE AND RISE IN OBESITY
3.1.4. INNOVATIONS AND DEVELOPMENT OF NEW PRODUCTS
3.2. RESTRAINTS
3.2.1. REIMBURSEMENTS AND STRICT GOVERNMENT REGULATIONS
3.2.2. LIMITED AWARENESS AND AVAILABILITY
3.3. OPPORTUNITIES
3.3.1. ROBUST PIPELINE PRODUCTS
3.3.2. EMERGING MARKETS
4. MARKET SEGMENTATION
4.1. RESPIRATORY DRUGS MARKET BY DRUG
4.1.1. ADVAIR
4.1.2. SYMBICORT TURBUHALER
4.1.3. SPIRIVA
4.1.4. XOLAIR
4.1.5. VENTOLIN
4.1.6. PULMICORT
4.1.7. ORKAMBI
4.1.8. RELVAR/BREO ELLIPTA
4.1.9. SINGULAIR
4.1.10. ESBRIET
4.1.11. KALYDECO
4.1.12. EPIPEN
4.1.13. OFEV
4.1.14. OTHER
4.2. RESPIRATORY DRUGS MARKET BY DRUG CLASS
4.2.1. ANTICHOLINERGICS
4.2.2. ANTIHISTAMINES
4.2.3. BETA2 AGONISTS
4.2.4. ANTIASTHMATIC COMBINATIONS
4.2.5. CORTICOSTEROIDS
4.2.6. LEUKOTRIENE INHIBITORS
4.2.7. MAST CELL STABILIZERS
4.2.8. PHOSPHODIESTERASE 4 (PDE4) INHIBITORS
4.2.9. BRONCHODILATORS
4.2.10. DECONGESTANTS
4.2.11. EXPECTORANTS
4.2.12. OTHER RESPIRATORY DRUGS
4.3. RESPIRATORY DRUGS MARKET BY ROUTE OF ADMINISTRATION
4.3.1. ORAL RESPIRATORY DRUGS
4.3.2. INJECTABLE RESPIRATORY DRUGS
4.3.3. INHALABLE RESPIRATORY DRUGS
4.4. RESPIRATORY DRUGS MARKET BY END USERS
4.4.1. HOSPITALS
4.4.2. HOME CARE
4.4.3. OTHER END USERS
5. COMPETITIVE LANDSCAPE
5.1. MARKET SHARE ANALYSIS
5.2. KEY COMPANY ANALYSIS
6. REGIONAL ANALYSIS
6.1. NORTH AMERICA
6.1.1. UNITED STATES
6.1.2. CANADA
6.1.3. REST OF NORTH AMERICA
6.2. EUROPE
6.2.1. UNITED KINGDOM
6.2.2. FRANCE
6.2.3. GERMANY
6.2.4. ITALY
6.2.5. SPAIN
6.2.6. REST OF EUROPE
6.3. ASIA PACIFIC
6.3.1. INDIA
6.3.2. CHINA
6.3.3. JAPAN
6.4. REST OF THE WORLD
7. COMPANY PROFILES
7.1. AIR LIQUIDE
7.2. ARADIGM CORPORATION
7.3. ASTRAZENECA PLC
7.4. BAXTER INTERNATIONAL INC.
7.5. BEXIMCO PHARMACEUTICALS LTD.
7.6. BOEHRINGER INGELHEIM GMBH
7.7. COMPUMEDICS LTD.
7.8. COVIDIEN PLC
7.9. DRAGER MEDICAL GMBH
7.10. F. HOFFMANN-LA ROCHE LTD
7.11. FISHER AND PAYKEL HEALTHCARE CORP. LTD
7.12. GE HEALTHCARE LIMITED
7.13. GENENTECH, INC.
7.14. GLAXOSMITHKLINE PLC
7.15. GRIFOLS, S.A.
7.16. HAMILTON MEDICAL AG
7.17. INVACARE CORPORATION
7.18. KONINKLIJKE PHILIPS N.V.
7.19. MERCK AND CO.
7.20. METHAPHARM, INC.
7.21. MYLAN N.V.
7.22. NABRIVA THERAPEUTICS PLC
7.23. NEPHRON PHARMACEUTICALS CORPORATION
7.24. NOVABIOTICS LTD.
7.25. NOVALUNG GMBH
7.26. NOVARTIS INTERNATIONAL AG
7.27. OMRON CORPORATION
7.28. OPKO HEALTH, INC.
7.29. OREXO AB
7.30. OTSUKA PHARMACEUTICALS INC.
7.31. PALOBIOFARMA S.L.
7.32. PFIZER INC.
7.33. SAVARA, INC.
7.34. SUMITOMO DAINIPPON PHARMA CO., LTD.
7.35. SUNOVION PHARMACEUTICALS INC.
7.36. TAKEDA PHARMACEUTICAL COMPANY LIMITED
7.37. TEVA PHARMACEUTICALS INC.
7.38. UNITED THERAPEUTICS CORPORATION
7.39. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
7.40. VERONA PHARMA PLC
7.41. VERTEX PHARMACEUTICALS INC.
LIST OF TABLES
TABLE 1 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023 ($ MILLION)
TABLE 2 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
TABLE 3 GLOBAL ADVAIR MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 4 GLOBAL SYMBICORT TURBUHALER MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 5 GLOBAL SPIRIVA MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 6 GLOBAL XOLAIR MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 7 GLOBAL VENTOLIN MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 8 GLOBAL PULMICORT MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 9 GLOBAL ORKAMBI MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 10 GLOBAL RELVAR/BREO ELLIPTA MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 11 GLOBAL SINGULAIR MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 12 GLOBAL ESBRIET MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 13 GLOBAL KALYDECO MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 14 GLOBAL EPIPEN MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 15 GLOBAL OFEV MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 16 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 17 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
TABLE 18 GLOBAL ORAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 19 GLOBAL INJECTABLE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 20 GLOBAL INHALABLE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 21 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023 ($ MILLION)
TABLE 22 GLOBAL ANTICHOLINERGICS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 23 GLOBAL ANTIHISTAMINES MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 24 GLOBAL BETA2 AGONISTS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 25 GLOBAL ANTIASTHMATICS COMBINATIONS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 26 GLOBAL CORTICOSTEROIDS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 27 GLOBAL LEUKOTRIENE INHIBITORS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 28 GLOBAL MAST CELL STABILIZERS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 29 GLOBAL PDE4 INHIBITORS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 30 GLOBAL BRONCHODILATORS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 31 GLOBAL DECOGESTANTS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 32 GLOBAL EXPECTORANTS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 33 GLOBAL OTHER RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 34 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)
TABLE 35 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS BY APPLICATIONS 2017-2023 ($ MILLION)
TABLE 36 GLOBAL HOME CARE MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 37 GLOBAL OTHER END USERS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 38 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
TABLE 39 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023 ($ MILLION)
TABLE 40 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUGS CLASS 2017-2023 ($ MILLION)
TABLE 41 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)
TABLE 42 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
TABLE 43 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
TABLE 44 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023 ($ MILLION)
TABLE 45 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUGS CLASS 2017-2023 ($ MILLION)
TABLE 46 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)
TABLE 47 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
TABLE 48 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023 ($ MILLION)
TABLE 49 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
TABLE 50 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023 ($ MILLION)
TABLE 51 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)
TABLE 52 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
TABLE 53 REST OF THE WORLD RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
TABLE 54 REST OF THE WORLD RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
TABLE 55 REST OF THE WORLD RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023 ($ MILLION)
TABLE 56 REST OF THE WORLD RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)
TABLE 1 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023 ($ MILLION)
TABLE 2 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
TABLE 3 GLOBAL ADVAIR MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 4 GLOBAL SYMBICORT TURBUHALER MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 5 GLOBAL SPIRIVA MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 6 GLOBAL XOLAIR MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 7 GLOBAL VENTOLIN MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 8 GLOBAL PULMICORT MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 9 GLOBAL ORKAMBI MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 10 GLOBAL RELVAR/BREO ELLIPTA MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 11 GLOBAL SINGULAIR MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 12 GLOBAL ESBRIET MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 13 GLOBAL KALYDECO MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 14 GLOBAL EPIPEN MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 15 GLOBAL OFEV MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 16 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 17 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
TABLE 18 GLOBAL ORAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 19 GLOBAL INJECTABLE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 20 GLOBAL INHALABLE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 21 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023 ($ MILLION)
TABLE 22 GLOBAL ANTICHOLINERGICS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 23 GLOBAL ANTIHISTAMINES MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 24 GLOBAL BETA2 AGONISTS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 25 GLOBAL ANTIASTHMATICS COMBINATIONS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 26 GLOBAL CORTICOSTEROIDS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 27 GLOBAL LEUKOTRIENE INHIBITORS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 28 GLOBAL MAST CELL STABILIZERS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 29 GLOBAL PDE4 INHIBITORS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 30 GLOBAL BRONCHODILATORS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 31 GLOBAL DECOGESTANTS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 32 GLOBAL EXPECTORANTS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 33 GLOBAL OTHER RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 34 GLOBAL RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)
TABLE 35 GLOBAL HOSPITALS MARKET RESEARCH AND ANALYSIS BY APPLICATIONS 2017-2023 ($ MILLION)
TABLE 36 GLOBAL HOME CARE MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 37 GLOBAL OTHER END USERS MARKET RESEARCH AND ANALYSIS 2017-2023 ($ MILLION)
TABLE 38 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
TABLE 39 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023 ($ MILLION)
TABLE 40 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUGS CLASS 2017-2023 ($ MILLION)
TABLE 41 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)
TABLE 42 NORTH AMERICA RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
TABLE 43 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
TABLE 44 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023 ($ MILLION)
TABLE 45 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUGS CLASS 2017-2023 ($ MILLION)
TABLE 46 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)
TABLE 47 EUROPE RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
TABLE 48 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023 ($ MILLION)
TABLE 49 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
TABLE 50 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY 2017-2023 ($ MILLION)
TABLE 51 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)
TABLE 52 APAC RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
TABLE 53 REST OF THE WORLD RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG 2017-2023 ($ MILLION)
TABLE 54 REST OF THE WORLD RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY ROUTE OF ADMINISTRATION 2017-2023 ($ MILLION)
TABLE 55 REST OF THE WORLD RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY DRUG CLASS 2017-2023 ($ MILLION)
TABLE 56 REST OF THE WORLD RESPIRATORY DRUGS MARKET RESEARCH AND ANALYSIS BY END USERS 2017-2023 ($ MILLION)
LIST OF FIGURES
FIGURE 1 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY DRUG 2017 VS 2023 (IN %)
FIGURE 2 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY ROUTE OF ADMINISTRATION 2017 VS 2023 (IN %)
FIGURE 3 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY DRUGS CLASS 2017 VS 2023 (IN %)
FIGURE 4 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY END USERS 2017 VS 2023 (IN %)
FIGURE 5 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY GEOGRAPHY 2017 VS 2023 (IN %)
FIGURE 6 NORTH AMERICA RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 7 US RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 8 CANADA RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 9 EUROPEAN RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 10 UK RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 11 FRANCE RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 12 GERMANY RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 13 ITALY RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 14 SPAIN RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 15 ROE RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 16 ASIA PACIFIC RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 17 INDIA RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 18 CHINA RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 19 JAPAN RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 20 ROAPAC RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 21 REST OF THE WORLD RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
COMPANIES MENTIONED
1. AIR LIQUIDE
2. ARADIGM CORPORATION
3. ASTRAZENECA PLC
4. BAXTER INTERNATIONAL INC.
5. BEXIMCO PHARMACEUTICALS LTD.
6. BOEHRINGER INGELHEIM GMBH
7. COMPUMEDICS LTD.
8. COVIDIEN PLC
9. DRAGER MEDICAL GMBH
10. F. HOFFMANN-LA ROCHE LTD
11. FISHER AND PAYKEL HEALTHCARE CORP. LTD
12. GE HEALTHCARE LIMITED
13. GENENTECH, INC.
14. GLAXOSMITHKLINE PLC
15. GRIFOLS, S.A.
16. HAMILTON MEDICAL AG
17. INVACARE CORPORATION
18. KONINKLIJKE PHILIPS N.V.
19. MERCK AND CO.
20. METHAPHARM, INC.
21. MYLAN N.V.
22. NABRIVA THERAPEUTICS PLC
23. NEPHRON PHARMACEUTICALS CORPORATION
24. NOVABIOTICS LTD.
25. NOVALUNG GMBH
26. NOVARTIS INTERNATIONAL AG
27. OMRON CORPORATION
28. OPKO HEALTH, INC.
29. OREXO AB
30. OTSUKA PHARMACEUTICALS INC.
31. PALOBIOFARMA S.L.
32. PFIZER INC.
33. SAVARA, INC.
34. SUMITOMO DAINIPPON PHARMA CO., LTD.
35. SUNOVION PHARMACEUTICALS INC.
36. TAKEDA PHARMACEUTICAL COMPANY LIMITED
37. TEVA PHARMACEUTICALS INC.
38. UNITED THERAPEUTICS CORPORATION
39. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
40. VERONA PHARMA PLC
41. VERTEX PHARMACEUTICALS INC.
FIGURE 1 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY DRUG 2017 VS 2023 (IN %)
FIGURE 2 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY ROUTE OF ADMINISTRATION 2017 VS 2023 (IN %)
FIGURE 3 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY DRUGS CLASS 2017 VS 2023 (IN %)
FIGURE 4 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY END USERS 2017 VS 2023 (IN %)
FIGURE 5 GLOBAL RESPIRATORY DRUGS MARKET SHARE BY GEOGRAPHY 2017 VS 2023 (IN %)
FIGURE 6 NORTH AMERICA RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 7 US RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 8 CANADA RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 9 EUROPEAN RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 10 UK RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 11 FRANCE RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 12 GERMANY RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 13 ITALY RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 14 SPAIN RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 15 ROE RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 16 ASIA PACIFIC RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 17 INDIA RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 18 CHINA RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 19 JAPAN RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 20 ROAPAC RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
FIGURE 21 REST OF THE WORLD RESPIRATORY DRUGS MARKET SIZE 2017-2023 ($MILLION)
COMPANIES MENTIONED
1. AIR LIQUIDE
2. ARADIGM CORPORATION
3. ASTRAZENECA PLC
4. BAXTER INTERNATIONAL INC.
5. BEXIMCO PHARMACEUTICALS LTD.
6. BOEHRINGER INGELHEIM GMBH
7. COMPUMEDICS LTD.
8. COVIDIEN PLC
9. DRAGER MEDICAL GMBH
10. F. HOFFMANN-LA ROCHE LTD
11. FISHER AND PAYKEL HEALTHCARE CORP. LTD
12. GE HEALTHCARE LIMITED
13. GENENTECH, INC.
14. GLAXOSMITHKLINE PLC
15. GRIFOLS, S.A.
16. HAMILTON MEDICAL AG
17. INVACARE CORPORATION
18. KONINKLIJKE PHILIPS N.V.
19. MERCK AND CO.
20. METHAPHARM, INC.
21. MYLAN N.V.
22. NABRIVA THERAPEUTICS PLC
23. NEPHRON PHARMACEUTICALS CORPORATION
24. NOVABIOTICS LTD.
25. NOVALUNG GMBH
26. NOVARTIS INTERNATIONAL AG
27. OMRON CORPORATION
28. OPKO HEALTH, INC.
29. OREXO AB
30. OTSUKA PHARMACEUTICALS INC.
31. PALOBIOFARMA S.L.
32. PFIZER INC.
33. SAVARA, INC.
34. SUMITOMO DAINIPPON PHARMA CO., LTD.
35. SUNOVION PHARMACEUTICALS INC.
36. TAKEDA PHARMACEUTICAL COMPANY LIMITED
37. TEVA PHARMACEUTICALS INC.
38. UNITED THERAPEUTICS CORPORATION
39. VALEANT PHARMACEUTICALS INTERNATIONAL, INC.
40. VERONA PHARMA PLC
41. VERTEX PHARMACEUTICALS INC.
